As the activation of inflammatory pathway is a crucial pathological event in the occurrence and development of HF (Mann, 2002), and IL-6 is one of the most well-characterized and principal cytokines in cardiovascular disease (Askevold et al., 2014), understanding the specific role of IL-6 in HF counts for the target therapy in HF. This evidence concerns the gene IL6 and cardiovascular disorder.